12:00 AM
Jul 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RXI-109: Phase I started

RXi began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial to evaluate RXI-109 in patients. Earlier this year, Galena Biopharma Inc. (NASDAQ:GALE, Lake...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >